Showing results (111-120 of 152) with videos related to

Sort By:
Pageof 16
JCO Oncology Practice|May 27, 2025
Medically Integrated Dispensing Pharmacy: ASCO-Network for Collaborative Oncology Development & Advancement Standards UpdateLuis E Raez, Xylina T Gregg, Gurjyot K Doshi, et al.
Translational Oncology|July 29, 2023
Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subsetMisako Nagasaka, Danielle Brazel, Yasmine Baca, et al.
Expert Review of Anticancer Therapy|April 16, 2025
Prevalence and molecular correlates of acquired <i>EGFR</i> resistance mutations in non-small cell lung cancer (NSCLC)Luis E Raez, Yasmine Baca, Jennifer R Ribeiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2018
Exosome-Based Detection of <i>EGFR</i> T790M in Plasma from Non-Small Cell Lung Cancer PatientsElena Castellanos-Rizaldos, Dominik G Grimm, Vasisht Tadigotla, et al.
Molecular Cancer|April 20, 2024
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulationAnder Puyalto, María Rodríguez-Remírez, Inés López, et al.
Critical Reviews in Oncology/Hematology|May 20, 2020
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)Christian Rolfo, Andrés F Cardona, Massimo Cristofanilli, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 14, 2003
High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodesMonic J Stuart, William P Peters, Gloria Broadwater, et al.
Frontiers in Oncology|September 13, 2023
Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancerRobert Hsu, Denaly Chen, Bing Xia, et al.
Cancer Chemotherapy and Pharmacology|December 12, 2012
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumorsLuis E Raez, Kyriakos Papadopoulos, Alejandro D Ricart, et al.
Oncology and Therapy|October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a VodcastBalazs Halmos, Narjust Florez, Sarah Goldberg, et al.
Pageof 16